GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » PB Ratio

PDS Biotechnology (PDS Biotechnology) PB Ratio : 4.14 (As of Apr. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-27), PDS Biotechnology's share price is $3.27. PDS Biotechnology's Book Value per Share for the quarter that ended in Dec. 2023 was $0.79. Hence, PDS Biotechnology's PB Ratio of today is 4.14.

The historical rank and industry rank for PDS Biotechnology's PB Ratio or its related term are showing as below:

PDSB' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 12.2
Current: 4.14

During the past 11 years, PDS Biotechnology's highest PB Ratio was 12.20. The lowest was 0.00. And the median was 0.00.

PDSB's PB Ratio is ranked worse than
70.89% of 1309 companies
in the Biotechnology industry
Industry Median: 2.38 vs PDSB: 4.14

During the past 12 months, PDS Biotechnology's average Book Value Per Share Growth Rate was -45.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -13.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -37.70% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of PDS Biotechnology was -13.00% per year. The lowest was -68.90% per year. And the median was -45.20% per year.

Back to Basics: PB Ratio


PDS Biotechnology PB Ratio Historical Data

The historical data trend for PDS Biotechnology's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology PB Ratio Chart

PDS Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.20 1.76 3.65 9.05 6.29

PDS Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.05 4.61 4.79 6.39 6.29

Competitive Comparison of PDS Biotechnology's PB Ratio

For the Biotechnology subindustry, PDS Biotechnology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's PB Ratio distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's PB Ratio falls into.



PDS Biotechnology PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

PDS Biotechnology's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=3.27/0.79
=4.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


PDS Biotechnology  (NAS:PDSB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


PDS Biotechnology PB Ratio Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PDS Biotechnology (PDS Biotechnology) Business Description

Traded in Other Exchanges
Address
25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932
PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Executives
Spencer D. Brown officer: Senior VP, General Counsel 25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill officer: Chief Financial Officer C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist director, 10 percent owner RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King officer: Interim Chief Financial Office 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev director 303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk officer: Principal Accounting Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes director C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo director, 10 percent owner, officer: President/CEO 300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood officer: Chief Medical Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn officer: Chief Scientific Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922

PDS Biotechnology (PDS Biotechnology) Headlines

From GuruFocus